Prelude Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company has shifted its focus to JAK2V617F and KAT6A programs, targeting clinical entry in 2026, and is advancing a novel CALR degrader. Mutant-selective approaches and strategic partnerships, including a deal with Incyte, support a strong financial runway into 2027.
Fiscal Year 2025
-
Secured $60M upfront and up to $910M in total from Incyte for the JAK2 V617F program, supporting clinical advancement of two lead oncology assets into 2026–2027. Both programs target large, high-need markets with differentiated, selective approaches and robust preclinical data.
-
Clinical programs for SMARCA2 degraders are advancing, with IV and oral agents showing promising efficacy and safety, especially in lung and upper GI cancers. The pipeline includes a selective CDK6 degrader and ADC collaborations, supported by a strong cash position into 2026.
-
Lead SMARCA2 programs show promising safety and efficacy, with both IV and oral candidates advancing quickly in aggressive cancer types. Pipeline expansion includes a selective CAT6A degrader and antibody conjugates, with strong preclinical data and new clinical milestones expected in 2024–2025.
-
Advancing SMARCA2 and KAT6A degrader programs, with strong early efficacy and rapid clinical progress. Oral and IV assets are being developed in parallel, supported by a solid cash position and active business development. Regulatory outlook remains positive.
-
Current macro and regulatory changes are not expected to disrupt operations, with proactive supply chain management in place. Lead SMARCA pathway degraders show promising early clinical results, and both IV and oral programs are advancing, with a major data update expected in H2 2025.
Fiscal Year 2024
-
The summit highlighted progress in developing first-in-class SMARCA2 degraders for cancers with SMARCA4 mutations, with promising early clinical data and ongoing combination studies. Key milestones in 2025 include dose selection, expanded clinical data, and strategic prioritization of IV and oral programs.
-
PRT3789, a selective SMARCA2 degrader, showed promising safety and early efficacy in heavily pretreated SMARCA4-mutated cancers, with partial responses and prolonged stable disease observed. Dose escalation and combination studies are ongoing, and an oral SMARCA2 degrader has entered clinical trials.
-
The presentation outlined a robust precision oncology pipeline, with lead SMARCA2 and CDK9 programs advancing through clinical trials and multiple data readouts expected this year. Strategic partnerships and novel approaches aim to address high unmet needs in oncology.
-
Focused on precision oncology, the company advances its SMARCA2 and CDK9 programs, with key phase 1 data updates expected later this year. Both IV and oral SMARCA2 candidates are progressing, and a strong cash position supports ongoing global trials and potential partnerships.